Insmed Inc (INSM) Stock Price, Quote & News

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor o...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 977 9900

Website: www.insmed.com

Address:

700 US Highway 202/206, Bridgewater, United States

Chasetae Aug. 17 at 8:16 PM

$INSM when it runs at $135 it will blow through like a hot knife through butter.

0 · Reply

JimmyOcarri Aug. 17 at 7:58 PM

$FUTU $ICLR $MDGL $MTSI $INSM like

0 · Reply

PhishTourFunds Aug. 17 at 1:28 AM

$INSM HCW major upgrade like that is something I can get behind

1 · Reply

pianoman439 Aug. 16 at 9:54 PM

$INSM Mizuho new modeling base case PT of $192 is based on key assumptions around (1) current ongoing launches of currently approved Arikayce in refractory NTM-MAC &brensocatib in NCFBE, as well as launch timings of Arikayce in front-line NTM-MAC, and TPIP in PH-ILD, PAH, and IPF (2) speed of market adoptions and depth of market penetration in all of INSM’s indications, and (3) LOE assumptions and potential generic entry, where notably, do not assume any LOE for INSM’s products. bull case is $280; this primarily assumes 80% peak market share for brensocatib in NCFBE (vs. current base case 65% peak market share”

0 · Reply

manavis4 Aug. 12 at 5:49 PM

$LQDA When do folks sober up to the threat that $INSM pipleline poses?

2 · Reply

pianoman439 Aug. 10 at 5:20 PM

$INSM Truist and H.C. Wainwright weigh in, 195 & 220 respectively.

0 · Reply

55X_ROI_Q1_2026 Aug. 10 at 5:43 AM

$SLS $INSM $XBI Official Title of the Gps Phase 2 CR1 Trial: Phase 2 Trial of a WT1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) GPS Phase 2 MOS for FIRST REMISSION Patients not Candidates for Transplant was Not yet reached and > Greater than 67.6 months BAT - in the Same CR1 Setting is 17.3 months. it is not complicated. https://clinicaltrials.gov/study/NCT01266083?id=NCT05934513&term=NCT01266083&rank=1

0 · Reply

pianoman439 Aug. 9 at 12:53 AM

$INSM Cantor clarifies that the bearish thesis is over for Insmed, believes price will reflect it in the near future with approximate 50% increase.

0 · Reply

JodieChristy Aug. 7 at 9:46 PM

Biotech Valuation Overload? My Top 4 High-Conviction Value Picks To Outsmart The Market! $INSM is trading strong around $131.10 right now! $PTGX is trading strong around $146.00 right now! $BBIO is trading strong around $84.48 right now! $PRAX is trading strong around $360.76 right now! While the broader biotech sector looks insanely overvalued, I filter strictly for late-stage clinical or early commercial winners featuring elite management, massive broad pipelines, $10B+ peak sales potential, and prices at or below intrinsic value. My current high-conviction watchlist features exactly four names: $INSM,$PTGX, $BBIO, and$PRAX.[Live Trading Strategy]: Avoid chasing overpriced hype scale into key support levels methodically and let value do the heavy lifting!

2 · Reply

55X_ROI_Q1_2026 Aug. 7 at 8:43 PM

$SLS $INSM Increased Revenue and ensuiing increase in projected Rev to $1.75B / Added $10B in Market Value in 1 Day - Co now worth $29B. $29B based on Projected Revenue of < $2B Gps, a revolutionary Immunotherapy for AML, Ovarian, Mesothelioma REMISSION MAINTENANCE will Generate Tens of Billions each year. • Gps Rev Projection of $5B just for CR2/3 AML Remission. SLS is the most manipulated / under valued equity in the Market. This $2B Baby Bio is going to ADD $20B the Instant Gps Phase 3 Results are announced.

0 · Reply

Market Cap	28.02B
Revenue (ttm)	606.42M
Net Income (ttm)	-1.28B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-210.54%
Debt to Equity Ratio	0.72

Volume	1,274,000
Avg Vol	3,674,572
Day's Range	N/A - N/A
Shares Out	218.38M
Stochastic %K	40%
Beta	0.81
Analysts	Strong Sell
Price Target	$196.65